Osiris Therapeutics (OSIR) Trades Strong Following Prochymal News; Shares Nearly at Annual Highs
Tweet Send to a FriendGet Alerts OSIR Hot Sheet
Trade OSIR Now!
Osiris Therapeutics, Inc. (Nasdaq: OSIR) shares are moving today on strong volume following an earlier announcement it received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.
Volatility on the stock is up 22 points from Wednesday to 96.85 percent.
Shares are up over 11 percent on the session. Earlier, shares were inching closer to a fresh 52-week high at $8.39. Today is actually the highest level shares have been since last July.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Volatility on the stock is up 22 points from Wednesday to 96.85 percent.
Shares are up over 11 percent on the session. Earlier, shares were inching closer to a fresh 52-week high at $8.39. Today is actually the highest level shares have been since last July.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amid Tesla (TSLA) Squeeze, Option Prices Hit Record Highs
- JCPenney (JCP) Meeting Peer Performace Could Provide for Prodigious Profits
- Samsung Boasts About Galaxy S4 Sales; Apple (AAPL) on Watch
Create E-mail Alert Related Categories
Insiders' Blog, Options
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
